634 related articles for article (PubMed ID: 32921006)
1. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives.
Cho KH; Hong YJ
Korean J Intern Med; 2020 Sep; 35(5):1045-1058. PubMed ID: 32921006
[TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
3. Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors.
Eisen A; Giugliano RP
Curr Opin Cardiol; 2016 Nov; 31(6):644-653. PubMed ID: 27661220
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
Schwartz GG; Giugliano RP
Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
[TBL] [Abstract][Full Text] [Related]
5. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
Board C; Kelly MS; Shapiro MD; Dixon DL
J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
Bittner VA; Giugliano RP; Brinton EA; Guyton JR
J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of PCSK9 monoclonal antibodies.
Iqbal Z; Dhage S; Mohamad JB; Abdel-Razik A; Donn R; Malik R; Ho JH; Liu Y; Adam S; Isa B; Stefanutti C; Soran H
Expert Opin Drug Saf; 2019 Dec; 18(12):1191-1201. PubMed ID: 31623472
[No Abstract] [Full Text] [Related]
10. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
Mahmood T; Shapiro MD
Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.
Turgeon RD; Pearson GJ
Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110
[TBL] [Abstract][Full Text] [Related]
12. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
13. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
Pirillo A; Catapano AL
Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
[TBL] [Abstract][Full Text] [Related]
14. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience.
Pandey AS; Bajaj HS; Garg V; Pandey A; Verma S
Curr Opin Cardiol; 2017 Sep; 32(5):633-641. PubMed ID: 28557865
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 inhibitors in the prevention of cardiovascular disease.
Latimer J; Batty JA; Neely RD; Kunadian V
J Thromb Thrombolysis; 2016 Oct; 42(3):405-19. PubMed ID: 27095708
[TBL] [Abstract][Full Text] [Related]
17. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
Tziomalos K
Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association.
Robinson JG; Jayanna MB; Brown AS; Aspry K; Orringer C; Gill EA; Goldberg A; Jones LK; Maki K; Dixon DL; Saseen JJ; Soffer D
J Clin Lipidol; 2019; 13(4):525-537. PubMed ID: 31281070
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
20. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N
Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]